Answers to Key Questions About Antibody–Drug Conjugates in NSCLC
Answers to Key Questions About Antibody–Drug Conjugates in NSCLC Chair and Presenter, Benjamin Levy, MD, Melissa L. Johnson, MD, Stephen V. Liu, MD, and Christine M. Lovly, MD, PhD, discuss NSCLC in this CME/MOC activity titled “Peer Pressure: How Well Do You Know Your ADCs? Answers to Key Questions About Antibody–Drug Conjugates in NSCLC.” For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC information, and to apply for credit, please visit us at PeerView.com/PJD865. CME/MOC credit will be available until March 23, 2024.

▶︎
Antibody–Drug Conjugates for Solid Tumors: Progress, Possibilities, and Implications for Care

▶︎
Innovation Takes the Stage in HNSCC

▶︎
Safety Considerations for the Development of Antibody Drug Conjugates

▶︎
How Dopamine & Serotonin Shape Decisions, Motivation & Learning | Dr. Read Montague

▶︎
Rocky Mountain IBD- March 14- Saturday Morning Recording

▶︎
Innovations in Pediatric HCM Care: The SCOUT-HCM Clinical Trial of Mavacamten

▶︎
SABCS 2024: People's choice - future directions in antibody drug conjugates

▶︎
Clinical Pearls for Subcutaneous Delivery: Optimizing Anti-CD38 Delivery in Multiple Myeloma

▶︎
Improve Energy & Longevity by Optimizing Mitochondria | Dr. Martin Picard

▶︎
SABCS 2023: Toxicity Management - Next Gen Therapies Means Next Gen Toxicities

▶︎
The Promise of Oral Therapy for HER2-Mutated NSCLC: Unlocking NewTreatment Opportunities

▶︎
Medical breakthroughs and health stories | 60 Minutes Marathon

▶︎
TROP2-Targeting ADCs as New Tools in the TNBC and HR+/HER2- Breast Cancer Treatment Arsenal

▶︎
#3 2025 08 23 Cancer Center Lynch Syndrome Symposium Preventing Cancers in Lynch Syndrome

▶︎
The Complete Cardiology Masterclass: Exam-Ready in One Video

▶︎
Lung Cancer Breakout: Breakthrough treatments for longer life

▶︎
CAOH 2025: Ana C Garrido Castro, MD - Assistant Professor of Medicine, Dana Farber Cancer Institute

▶︎
Baim Grand Rounds Katherine Tuttle 15Jun2026

▶︎
New Strategies to Improve Outcomes of Non-HPV-Associated Recurrent/Metastatic Head and Neck Cancer

▶︎
